A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone

Summary

The purpose of this research study is to compare the efficacy and safety of higher doses of rituximab to a combination of standard doses of Rituxan + CVP (Cyclophosphamide, Vincristine, and Prednisone) in patients with chronic Idiopathic Thrombocytopenic Purpura (ITP who did not respond to or relapsed after standard doses of rituximab.

Timeline

Start

2004-02

Primary completion

—

Completion

—

Drugs

Indications